Hiv

DENVER — Four children born with HIV who initiated ART within 48 hours of delivery later remained in treatment-free remission for over a year after ART was paused, researchers reported.

DENVER — A low weekly dose of semaglutide can safely minimize what used to be called nonalcoholic fatty liver disease in people with HIV, a first-of-its-kind study found.

DENVER — Long-acting injectable ART administered every 8 weeks safely suppresses HIV in adolescents, according to research presented at the Conference on Retroviruses and Opportunistic Infections.

DENVER — Phase 2 study data showed that a once-weekly oral regimen of an investigational two-drug HIV treatment was well tolerated among patients with HIV and allowed them to maintain viral suppression.

DENVER — The International Antiviral Society-USA (IAS-USA) has updated its HIV treatment guidelines to endorse the off-label use of long-acting injectable ART in patients with HIV viremia.

DENVER — New data from a cohort of adolescent and young women in sub-Saharan Africa showed a higher level of HIV PrEP adherence than has been reported in previous studies, researchers said.

DENVER — A new study provides reassurances that PrEP can reliably prevent HIV in cisgender women, even if they do not use it daily.

DENVER — Data from the United States and Australia show that PrEP uptake and adherence has increased, and the incidence of HIV has declined in recent years, researchers reported.

DENVER — As clinicians await national guidelines on its use, evidence continues to mount that doxy-PEP can help curtail the prolonged epidemic of sexually transmitted infections in the United States.

DENVER — A cocktail composed of three broadly neutralizing monoclonal antibodies resulted in long-term virologic control in people with HIV after they discontinued ART, researchers found.